With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

With growth in percutaneous fixes for the valve, surgeons at STS 2025 called for innovation, team-based care, and more data.

The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

CoreMedic announced that it picked up new funding in a Series B extension to support its transcatheter mitral valve repair ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has found.